A Three-dimensional Ex Vivo Viability Assay Reveals a Strong Correlation Between Response to Targeted Inhibitors and Mutation Status in Melanoma Lymph Node Metastases-Reference-Cited by-同舟云学术

A Three-dimensional Ex Vivo Viability Assay Reveals a Strong Correlation Between Response to Targeted Inhibitors and Mutation Status in Melanoma Lymph Node Metastases

Published:2019-07 Issue:7 Volume:12 Page:951-958
ISSN:1936-5233
Container-title:Translational Oncology
language:en
Short-container-title:Translational Oncology

Author:

Flørenes Vivi Ann,Flem-Karlsen Karine,McFadden Erin,Bergheim Inger Riise,Nygaard Vigdis,Nygård Vegard,Farstad Inger Nina,Øy Geir Frode,Emilsen Elisabeth,Giller-Fleten Karianne,Ree Anne Hansen,Flatmark Kjersti,Gullestad Hans Petter,Hermann Robert,Ryder Truls,Wernhoff Patrik,Mælandsmo Gunhild Mari

Publisher

Elsevier BV

Subject

Cancer Research,Oncology

Reference61 articles.

1. Latest advances in chemotherapeutic, targeted, and immune approaches in the treatment of metastatic melanoma;Shah;Mayo Clin Proc,2014

2. Combined BRAF and MEK inhibition versus BRAF inhibition alone in melanoma;Long;N Engl J Med,2014

3. Resistance to BRAF-targeted therapy in melanoma;Sullivan;Eur J Cancer,2013

4. Resistant mechanisms to BRAF inhibitors in melanoma;Manzano;Ann Transl Med,2016

5. Coexisting NRAS and BRAF mutations in primary familial melanomas with specific CDKN2A germline alterations;Jovanovic;J Invest Dermatol,2010

Cited by 8 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Ex vivo therapeutic screening of metastatic cSCC: A review of methodological considerations for clinical implementation;Experimental Dermatology;2024-04

2. AXL inhibition improves BRAF-targeted treatment in melanoma;Scientific Reports;2022-03-24

3. Novel Biomarkers and Druggable Targets in Advanced Melanoma;Cancers;2021-12-24

4. MX2 mediates establishment of interferon response profile, regulates XAF1, and can sensitize melanoma cells to targeted therapy;Cancer Medicine;2021-03-18

5. Precision Medicine in Oncology: In Vitro Drug Sensitivity and Resistance Test (DSRT) for Selection of Personalized Anticancer Therapy;Advanced Therapeutics;2020-01-16